1 Dimopoulos MA, Moreau P, Palumbo A, et al. Carfi lzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016; 17: 27–38. 2 Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–73. 3 Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117: 4691–95.
Meletios A Dimopoulos, Katja Weisel, Philippe Moreau, Larry Anderson, Darrell White, Jesús F. San Miguel, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, J. Dürig, Michel Pavic, Morten Salomo, Xiaoyong Yu, Tuong Vi Nguyen, Amine Bensmaine, Teresa Peluso, Mounir Zaki, Paul G. Richardson
David S. Siegel, Katja Weisel, Meletios A Dimopoulos, Rachid Baz, Paul G. Richardson, Michel Delforge, Kevin Song, Jesús F. San Miguel, Philippe Moreau, Xin Yu, Kevin Hong, Lars Sternås, Mohamed H. Zaki, Antonio Palumbo
Meletios A Dimopoulos, Rubén Niesvizky, Philippe Moreau, David S. Siegel, Roman Hájek, María‐Victoria Mateos, Michèle Cavo, Mei Huang, Anita Zahlten‐Kumeli, Katja Weisel
Discussion(0)
No comments yet. Be the first to comment.